文献速递骨质疏松与代谢性骨病

绝经后女性骨质疏松性骨折预防药物管理的成本节约分析

A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women.
PubMed 文献 · Osteoporos Int · 2025-08-01

该研究通过系统综述与Meta分析评估绝经后女性骨质疏松性骨折预防的药物管理,纳入30项随机对照试验共86,411例患者。结果显示药物治疗显著降低骨折风险(RR=0.70,p<0.001),双膦酸盐、激素替代治疗和生物制剂分别降低骨折风险31%、27%和40%。

要点

  • 30项RCT共86,411例患者显示药物治疗显著降低骨折风险(RR=0.70,p<0.001)。
  • 双膦酸盐降低骨折风险31%,激素替代治疗降低27%,生物制剂降低40%。

核心结论

  • 药物疗法,特别是双膦酸盐和激素治疗,能有效降低高危绝经后女性的骨折发生率并产生显著成本节约。
  • 通过系统层面的举措提高可及性、可负担性和依从性可减轻骨质疏松的经济负担。
  • 未来研究应优化治疗策略并评估新兴疗法的成本效益和长期可持续性。

研究设计与样本

  • 系统综述与Meta分析,纳入30项比较激素替代治疗、双膦酸盐或生物制剂与安慰剂的随机对照试验,共86,411例患者,采用随机效应模型合并数据。
  • 成本分析利用 Medicare 数据(包括成本和支出),通过从总节约中减去药物成本计算净节约,并进行10年预测以评估长期经济影响。

主要发现

  • Meta分析显示药物治疗显著降低骨折风险(RR=0.70,p<0.001)。
  • 激素替代治疗降低骨折风险27%,双膦酸盐降低31%,生物制剂降低40%。

临床怎么用

  • 原文结论指出药物疗法(特别是双膦酸盐和激素治疗)可有效降低高危绝经后女性的骨折发生率并产生显著成本节约,但未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Pharmacologic therapy reduces osteoporotic fractures and generates substantial cost savings. A meta-analysis of 30 RCTs showed bisphosphonates, HRT, and biologics lower fracture risk by 31%, 27%, and 40%, respectively. Cost analysis revealed net savings of up to $12.8 billion annually and up to $118 billion over the next 10 years. PURPOSE: Osteoporotic fractures are a significant concern among postmenopausal women, leading to substantial healthcare costs. This study aims to evaluate the cost savings associated with pharmacologic management in preventing osteoporotic fractures among postmenopausal women. METHODS: A systematic review and meta-analysis were conducted to evaluate pharmacologic interventions for osteoporotic fracture prevention in postmenopausal women and identified studies comparing HRT, bisphosphonates, and biologics to placebo. A random-effects model was used to pool data and assess fracture reduction. Cost analysis utilized Medicare data, including cost and expenditures. Net savings were calculated by subtracting drug costs from gross savings, with a 10-year projection estimating long-term economic impact. RESULTS: A meta-analysis of 30 randomized controlled trials (86,411 patients) showed a significant reduction in fracture risk with pharmacologic therapy (RR = 0.70, p < 0.001). HRT reduced fracture risk by 27%, bisphosphonates by 31%, and biologics by 40%. Cost analysis showed annual net savings of $3.35B for bisphosphonates, $3.01B for HRT, and $1.33B for biologics at $8600 per fracture. Over 10 years, HRT could reduce cumulative costs by $118B. CONCLUSIONS: Pharmacologic therapies, particularly bisphosphonates and hormone therapy, effectively reduce fracture incidence and generate substantial cost savings in high-risk postmenopausal women. Enhancing accessibility, affordability, and adherence through system-wide initiatives can mitigate osteoporosis's economic burden. Future research should optimize treatment strategies and assess emerging therapies for cost-effectiveness and long-term sustainability.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cassinat J, Wright V. A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women. Osteoporos Int. 2025. PMID: 40748369. doi:10.1007/s00198-025-07621-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。